{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T20:37:38Z","timestamp":1774384658911,"version":"3.50.1"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13555-026-01680-7","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:34:37Z","timestamp":1771306477000},"page":"1473-1497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of Hidradenitis Suppurativa in the United Arab Emirates (UAE): A Consensus Statement from the Emirates Dermatology Society"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7371-4509","authenticated-orcid":false,"given":"Ahmed","family":"Ameen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Albreiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Alnaeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muna","family":"Al Murrawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huda R.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghda","family":"Almaashari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"AL-Marzooqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawaher","family":"Alnaqbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussein A.","family":"Dayem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waqas","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srikumar","family":"Goturu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Hantirah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf","family":"Reda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos C.","family":"Zouboulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"1680_CR1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000431175","volume":"231","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GBE. Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology. 2015;231:184\u201390. https:\/\/doi.org\/10.1159\/000431175.","journal-title":"Dermatology"},{"key":"1680_CR2","unstructured":"Hidradenitis suppurativa: overview. https:\/\/www.aad.org\/public\/diseases\/a-z\/hidradenitis-suppurativa-overview. Accessed 15 Jul 2024"},{"key":"1680_CR3","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1001\/JAMADERMATOL.2021.1677","volume":"157","author":"A Jfri","year":"2021","unstructured":"Jfri A, Nassim D, O\u2019Brien E, Gulliver W, Nikolakis G, Zouboulis CC, et\u00a0al. Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis. JAMA Dermatol. 2021;157:924\u201331. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2021.1677.","journal-title":"JAMA Dermatol"},{"key":"1680_CR4","doi-asserted-by":"publisher","DOI":"10.1159\/000538727","author":"Y Binamer","year":"2025","unstructured":"Binamer Y, Samman O, Aldabagh A, Boushi J, Bouazzi D, Medianfar CE, et\u00a0al. Prevalence of hidradenitis suppurativa in Saudi Arabia. Dermatology. 2025. https:\/\/doi.org\/10.1159\/000538727.","journal-title":"Dermatology"},{"key":"1680_CR5","doi-asserted-by":"publisher","unstructured":"Alsadhan H, Alfawzan AI, Yaqoub A, Almoneef A, Almohideb M. Hidradenitis Suppurativa: Estimated Prevalence, Clinical Features, and Risk Factors in Riyadh, Saudi Arabia. Cureus. Springer Science and Business Media LLC. 2022. https:\/\/doi.org\/10.7759\/cureus.23029","DOI":"10.7759\/cureus.23029"},{"key":"1680_CR6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49390","author":"ER Agnese","year":"2023","unstructured":"Agnese ER, Tariche N, Sharma A, Gulati R, Springer Science and Business Media LLC. The pathogenesis and treatment of hidradenitis suppurativa. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.49390.","journal-title":"Cureus"},{"key":"1680_CR7","unstructured":"Theakston C, Henderson N, Skedgel C. Estimates and recommendations. https:\/\/www.ohe.org\/publications\/burden-hidradenitis-"},{"key":"1680_CR8","unstructured":"Melson C, Tate J, Carswell O. Call to action: improving the lives of people with hidradenitis suppurativa (HS). 2024."},{"key":"1680_CR9","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/ddg.15412","volume":"22","author":"CC Zouboulis","year":"2024","unstructured":"Zouboulis CC, Bechara FG, Fritz K, Goebeler M, Hetzer FH, Just E, et\u00a0al. S2k guideline for the treatment of hidradenitis suppurativa \/ acne inversa \u2013 Short version. J Dtsch Dermatol Ges. 2024;22:868\u201389. https:\/\/doi.org\/10.1111\/ddg.15412.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1680_CR10","doi-asserted-by":"publisher","unstructured":"Karvar M, Panayi AC, Alavi A, Baziar Z, Orgill DP. Trends in the management of hidradenitis suppurativa in the Middle East region: a systematic review. Int J Dermatol. 2021. https:\/\/doi.org\/10.1111\/ijd.15293","DOI":"10.1111\/ijd.15293"},{"key":"1680_CR11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/0030-5073(73)90052-4","volume":"9","author":"DH Gustafson","year":"1973","unstructured":"Gustafson DH, Shukla RK, Delbecq A, Walster GW. A comparative study of differences in subjective likelihood estimates made by individuals, interacting groups, Delphi groups, and nominal groups. Organ Behav Hum Perform. 1973;9:280\u201391. https:\/\/doi.org\/10.1016\/0030-5073(73)90052-4.","journal-title":"Organ Behav Hum Perform"},{"key":"1680_CR12","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S0016-3287(69)80025-X","volume":"1","author":"N Dalkey","year":"1969","unstructured":"Dalkey N. An experimental study of group opinion: the Delphi method. Futures. 1969;1:408\u201326. https:\/\/doi.org\/10.1016\/S0016-3287(69)80025-X.","journal-title":"Futures"},{"key":"1680_CR13","doi-asserted-by":"publisher","DOI":"10.2106\/00004623-200301000-00001","author":"JG Wright","year":"2003","unstructured":"Wright JG, Swiontkowski MF, Heckman JD. Introducing levels of evidence to the journal. J Bone Joint Surg Am. 2003. https:\/\/doi.org\/10.2106\/00004623-200301000-00001.","journal-title":"J Bone Joint Surg Am"},{"key":"1680_CR14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/00006199-198611000-00017","volume":"35","author":"MR Lynn","year":"1986","unstructured":"Lynn MR. Determination and quantification of content validity. Nurs Res. 1986;35:382\u20136. https:\/\/doi.org\/10.1097\/00006199-198611000-00017.","journal-title":"Nurs Res"},{"key":"1680_CR15","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/bjd.14038","volume":"173","author":"DM Saunte","year":"2015","unstructured":"Saunte DM, Boer J, Stratigos A, Szepietowski JC, Hamzavi I, Kim KH, et\u00a0al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173:1546\u20139. https:\/\/doi.org\/10.1111\/bjd.14038.","journal-title":"Br J Dermatol"},{"key":"1680_CR16","unstructured":"Hidradenitis suppurativa (HS)\u2014NHS. www.nhs.uk\/nhs-services\/"},{"key":"1680_CR17","unstructured":"Hidradenitis suppurativa: signs and symptoms. https:\/\/www.aad.org\/public\/diseases\/a-z\/hidradenitis-suppurativa-overview. Accessed 15 Jul 2024"},{"key":"1680_CR18","unstructured":"Kimberly Ballard A, Shuman Affiliations VL. Hidradenitis suppurativa continuing education activity."},{"key":"1680_CR19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1365-2133.1988.tb03227.x","volume":"119","author":"GBE Jemec","year":"1988","unstructured":"Jemec GBE. The symptomatology of hidradenitis suppurativa in women. Br J Dermatol. 1988;119:345\u201350. https:\/\/doi.org\/10.1111\/j.1365-2133.1988.tb03227.x.","journal-title":"Br J Dermatol"},{"key":"1680_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000488344","volume":"234","author":"SM Seyed\u00a0Jafari","year":"2018","unstructured":"Seyed\u00a0Jafari SM, Kn\u00fcsel E, Cazzaniga S, Hunger RE. A retrospective cohort study on patients with hidradenitis suppurativa. Dermatology. 2018;234:71\u20138. https:\/\/doi.org\/10.1159\/000488344.","journal-title":"Dermatology"},{"key":"1680_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/bjd.15939","volume":"178","author":"A Garg","year":"2018","unstructured":"Garg A, Papagermanos V, Midura M, Strunk A. Incidence of hidradenitis suppurativa among tobacco smokers: a population-based retrospective analysis in the U.S.A. Br J Dermatol. 2018;178:709\u201314. https:\/\/doi.org\/10.1111\/bjd.15939.","journal-title":"Br J Dermatol"},{"key":"1680_CR22","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1001\/jama.2017.16691","volume":"318","author":"DML Saunte","year":"2017","unstructured":"Saunte DML, Jemec GBE. Hidradenitis suppurativa. JAMA. 2017;318:2019. https:\/\/doi.org\/10.1001\/jama.2017.16691.","journal-title":"JAMA"},{"key":"1680_CR23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2147\/CCID.S351522","volume":"15","author":"K Yang","year":"2022","unstructured":"Yang K, Shi M, Fu C, Huo R. Comprehensive treatment of severe follicular occlusion triad: a case report. Clin Cosmet Investig Dermatol. 2022;15:541\u20136. https:\/\/doi.org\/10.2147\/CCID.S351522.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1680_CR24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.4103\/2229-5178.142517","volume":"5","author":"V Vasanth","year":"2014","unstructured":"Vasanth V, Chandrashekar B. Follicular occlusion tetrad. Indian Dermatol Online J. 2014;5:491. https:\/\/doi.org\/10.4103\/2229-5178.142517.","journal-title":"Indian Dermatol Online J"},{"key":"1680_CR25","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/DSS.0000000000001696","volume":"45","author":"AB Lyons","year":"2019","unstructured":"Lyons AB, Zubair R, Kohli I, Hamzavi IH. Preoperative ultrasound for evaluation of hidradenitis suppurativa. Dermatol Surg. 2019;45:294\u20136. https:\/\/doi.org\/10.1097\/DSS.0000000000001696.","journal-title":"Dermatol Surg"},{"key":"1680_CR26","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/DCR.0000000000000131","volume":"57","author":"N Griffin","year":"2014","unstructured":"Griffin N, Williams AB, Anderson S, Irving PM, Sanderson J, Desai N, et\u00a0al. Hidradenitis suppurativa. Dis Colon Rectum. 2014;57:762\u201371. https:\/\/doi.org\/10.1097\/DCR.0000000000000131.","journal-title":"Dis Colon Rectum"},{"key":"1680_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/exd.14633","volume":"31","author":"T Tzellos","year":"2022","unstructured":"Tzellos T, Zouboulis CC. Which hidradenitis suppurativa comorbidities should I take into account? Exp Dermatol. 2022;31:29\u201332. https:\/\/doi.org\/10.1111\/exd.14633.","journal-title":"Exp Dermatol"},{"key":"1680_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.811006","author":"I Mahmoud","year":"2022","unstructured":"Mahmoud I, Sulaiman N. Prevalence of metabolic syndrome and associated risk factors in the United Arab Emirates: a cross-sectional population-based study. Front Public Health. 2022. https:\/\/doi.org\/10.3389\/fpubh.2021.811006.","journal-title":"Front Public Health"},{"key":"1680_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","volume":"81","author":"A Alikhan","year":"2019","unstructured":"Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, et\u00a0al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2019;81:76\u201390. https:\/\/doi.org\/10.1016\/j.jaad.2019.02.067.","journal-title":"J Am Acad Dermatol"},{"key":"1680_CR30","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/ddg.15412","volume":"22","author":"CC Zouboulis","year":"2024","unstructured":"Zouboulis CC, Bechara FG, Fritz K, Goebeler M, Hetzer FH, Just E, et\u00a0al. S2k guideline for the treatment of hidradenitis suppurativa\/acne inversa\u2014Short version. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2024;22:868\u201389. https:\/\/doi.org\/10.1111\/ddg.15412.","journal-title":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft"},{"key":"1680_CR31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/bjd.14475","volume":"175","author":"JR Ingram","year":"2016","unstructured":"Ingram JR, Hadjieconomou S, Piguet V. Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process. Br J Dermatol. 2016;175:263\u201372. https:\/\/doi.org\/10.1111\/bjd.14475.","journal-title":"Br J Dermatol"},{"key":"1680_CR32","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/jdv.13216","volume":"30","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M, et\u00a0al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo\u2010controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30:989\u201394. https:\/\/doi.org\/10.1111\/jdv.13216.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1680_CR33","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1159\/000514582","volume":"237","author":"N Almuhanna","year":"2021","unstructured":"Almuhanna N, Finstad A, Alhusayen R. Association between hidradenitis suppurativa and inflammatory arthritis: a systematic review and meta-analysis. Dermatology. 2021;237:740\u20137. https:\/\/doi.org\/10.1159\/000514582.","journal-title":"Dermatology"},{"key":"1680_CR34","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1001\/jamadermatol.2019.0891","volume":"155","author":"W-T Chen","year":"2019","unstructured":"Chen W-T, Chi C-C. Association of hidradenitis suppurativa with inflammatory bowel disease. JAMA Dermatol. 2019;155:1022. https:\/\/doi.org\/10.1001\/jamadermatol.2019.0891.","journal-title":"JAMA Dermatol"},{"key":"1680_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/1203475419874411","volume":"24","author":"K Phan","year":"2020","unstructured":"Phan K, Huo YR, Charlton O, Smith SD. Hidradenitis suppurativa and thyroid disease: systematic review and meta-analysis. J Cutan Med Surg. 2020;24:23\u20137. https:\/\/doi.org\/10.1177\/1203475419874411.","journal-title":"J Cutan Med Surg"},{"key":"1680_CR36","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juh\u00e1sz I, et\u00a0al. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619\u201344. https:\/\/doi.org\/10.1111\/jdv.12966.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1680_CR37","doi-asserted-by":"publisher","unstructured":"Sachdeva M, Mufti A, Zaaroura H, Abduelmula A, Lansang RP, Bagit A, et\u00a0al. Squamous cell carcinoma arising within hidradenitis suppurativa: a literature review. Int J Dermatol. 2021. https:\/\/doi.org\/10.1111\/ijd.15677","DOI":"10.1111\/ijd.15677"},{"key":"1680_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9111594","volume":"9","author":"F Li Pomi","year":"2021","unstructured":"Li Pomi F, Macca L, Motolese A, Ingrasciotta Y, Berretta M, Guarneri C. Neoplastic implications in patients suffering from hidradenitis suppurativa under systemic treatments. Biomedicines. 2021;9:1594. https:\/\/doi.org\/10.3390\/biomedicines9111594.","journal-title":"Biomedicines"},{"key":"1680_CR39","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1159\/000509873","volume":"237","author":"G Nikolakis","year":"2021","unstructured":"Nikolakis G, Kaleta KP, Vaiopoulos AG, Wolter K, Baroud S, Wojas-Pelc A, et\u00a0al. Phenotypes and pathophysiology of syndromic hidradenitis suppurativa: different faces of the same disease? A systematic review. Dermatology. 2021;237:673\u201397. https:\/\/doi.org\/10.1159\/000509873.","journal-title":"Dermatology"},{"key":"1680_CR40","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2340\/00015555-1800","volume":"94","author":"C Kromann","year":"2014","unstructured":"Kromann C, Ibler K, Kristiansen V, Jemec G. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014;94:553\u20137. https:\/\/doi.org\/10.2340\/00015555-1800.","journal-title":"Acta Derm Venereol"},{"key":"1680_CR41","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/bjd.13090","volume":"171","author":"CB Kromann","year":"2014","unstructured":"Kromann CB, Deckers IE, Esmann S, Boer J, Prens EP, Jemec GBE. Risk factors, clinical course and long\u2010term prognosis in hidradenitis suppurativa: a cross\u2010sectional study. Br J Dermatol. 2014;171:819\u201324. https:\/\/doi.org\/10.1111\/bjd.13090.","journal-title":"Br J Dermatol"},{"key":"1680_CR42","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jaci.2022.02.003","volume":"149","author":"KR van Straalen","year":"2022","unstructured":"van Straalen KR, Prens EP, Gudjonsson JE. Insights into hidradenitis suppurativa. J Allergy Clin Immunol. 2022;149:1150\u201361. https:\/\/doi.org\/10.1016\/j.jaci.2022.02.003.","journal-title":"J Allergy Clin Immunol"},{"key":"1680_CR43","doi-asserted-by":"publisher","DOI":"10.1177\/20406223211055920","author":"V Amat-Samaranch","year":"2021","unstructured":"Amat-Samaranch V, Agut-Busquet E, Vilarrasa E, Puig L. New perspectives on the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis. 2021. https:\/\/doi.org\/10.1177\/20406223211055920.","journal-title":"Ther Adv Chronic Dis"},{"key":"1680_CR44","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.118.007448","volume":"12","author":"SK Sharma","year":"2019","unstructured":"Sharma SK, Tomey MI, Teirstein PS, Kini AS, Reitman AB, Lee AC, et\u00a0al. North American expert review of rotational atherectomy. Circ Cardiovasc Interv. 2019;12:e007448. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.118.007448.","journal-title":"Circ Cardiovasc Interv"},{"key":"1680_CR45","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/bjd.17537","volume":"180","author":"JR Ingram","year":"2019","unstructured":"Ingram JR, Collier F, Brown D, Burton T, Burton J, Chin MF, et\u00a0al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019;180:1009\u201317. https:\/\/doi.org\/10.1111\/bjd.17537.","journal-title":"Br J Dermatol"},{"key":"1680_CR46","first-page":"437","volume":"18","author":"C Marasca","year":"2019","unstructured":"Marasca C, Annunziata MC, Villani A, Volpe S, Marasca D, Fabbrocini G. Adalimumab versus rifampicin plus clindamycin for the treatment of moderate to severe hidradenitis suppurativa: a retrospective study. J Drugs Dermatol. 2019;18:437\u20138.","journal-title":"J Drugs Dermatol"},{"key":"1680_CR47","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1080\/09546634.2019.1655524","volume":"32","author":"FJ Garc\u00eda-Mart\u00ednez","year":"2021","unstructured":"Garc\u00eda-Mart\u00ednez FJ, Vilarrasa Rull E, Salgado-Boquete L, Martorell A, Pascual JC, Hern\u00e1ndez-Mart\u00edn \u00c1, et\u00a0al. Intralesional corticosteroid injection for the treatment of hidradenitis suppurativa: a multicenter retrospective clinical study. J Dermatolog Treat. 2021;32:286\u201390. https:\/\/doi.org\/10.1080\/09546634.2019.1655524.","journal-title":"J Dermatolog Treat"},{"key":"1680_CR48","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/DSS.0000000000002112","volume":"46","author":"K Fajgenbaum","year":"2020","unstructured":"Fajgenbaum K, Crouse L, Dong L, Zeng D, Sayed C. Intralesional triamcinolone may not be beneficial for treating acute hidradenitis suppurativa lesions: a double-blind, randomized, placebo-controlled trial. Dermatol Surg. 2020;46:685\u20139. https:\/\/doi.org\/10.1097\/DSS.0000000000002112.","journal-title":"Dermatol Surg"},{"key":"1680_CR49","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.91821","volume":"56","author":"N Puri","year":"2011","unstructured":"Puri N, Talwar A. A study on the management of hidradenitis suppurativa with retinoids and surgical excision. Indian J Dermatol. 2011;56:650. https:\/\/doi.org\/10.4103\/0019-5154.91821.","journal-title":"Indian J Dermatol"},{"key":"1680_CR50","doi-asserted-by":"publisher","first-page":"445","DOI":"10.25259\/IJDVL_471_19","volume":"88","author":"A-W Chen","year":"2022","unstructured":"Chen A-W, Chen Z, Bai X-M, Luo X-Y, Wang H. Successful treatment of early-onset hidradenitis suppurativa with acitretin in an infant with a novel mutation in PSENEN gene. Indian J Dermatol Venereol Leprol. 2022;88:445. https:\/\/doi.org\/10.25259\/IJDVL_471_19.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1680_CR51","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/09546634.2019.1670779","volume":"32","author":"N Patel","year":"2021","unstructured":"Patel N, McKenzie SA, Harview CL, Truong AK, Shi VY, Chen L, et\u00a0al. Isotretinoin in the treatment of hidradenitis suppurativa: a retrospective study. J Dermatolog Treat. 2021;32:473\u20135. https:\/\/doi.org\/10.1080\/09546634.2019.1670779.","journal-title":"J Dermatolog Treat"},{"key":"1680_CR52","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000477207","volume":"233","author":"CM Huang","year":"2017","unstructured":"Huang CM, Kirchhof MG. A new perspective on isotretinoin treatment of hidradenitis suppurativa: a retrospective chart review of patient outcomes. Dermatology. 2017;233:120\u20135. https:\/\/doi.org\/10.1159\/000477207.","journal-title":"Dermatology"},{"key":"1680_CR53","first-page":"155","volume":"150","author":"R Verdolini","year":"2015","unstructured":"Verdolini R, Simonacci F, Menon S, Pavlou P, Mannello B. Alitretinoin: a useful agent in the treatment of hidradenitis suppurativa, especially in women of child-bearing age. G Ital Dermatol Venereol. 2015;150:155\u201362.","journal-title":"G Ital Dermatol Venereol"},{"key":"1680_CR54","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2340\/00015555-1499","volume":"93","author":"S Prasad","year":"2013","unstructured":"Prasad S, Bygum A. Successful treatment with alitretinoin of dissecting cellulitis of the scalp in keratitis-ichthyosis-deafness syndrome. Acta Derm Venereol. 2013;93:473\u20134. https:\/\/doi.org\/10.2340\/00015555-1499.","journal-title":"Acta Derm Venereol"},{"key":"1680_CR55","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000182261","volume":"218","author":"A Soria","year":"2009","unstructured":"Soria A, Canoui-Poitrine F, Wolkenstein P, Poli F, Gabison G, Pouget F, et\u00a0al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients\u2019 outcome assessment. Dermatology. 2009;218:134\u20135. https:\/\/doi.org\/10.1159\/000182261.","journal-title":"Dermatology"},{"key":"1680_CR56","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4103\/ijabmr.IJABMR_469_16","volume":"7","author":"D Mondal","year":"2017","unstructured":"Mondal D, Shenoy R, Mishra S. Retinoic acid embryopathy. Int J Appl Basic Med Res. 2017;7:264. https:\/\/doi.org\/10.4103\/ijabmr.IJABMR_469_16.","journal-title":"Int J Appl Basic Med Res"},{"key":"1680_CR57","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1365-2133.1986.tb05740.x","volume":"115","author":"PS Mortimer","year":"1986","unstructured":"Mortimer PS, Dawber RPR, Gales MA, Moore RA. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol. 1986;115:263\u20138. https:\/\/doi.org\/10.1111\/j.1365-2133.1986.tb05740.x.","journal-title":"Br J Dermatol"},{"key":"1680_CR58","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/09546634.2019.1592100","volume":"31","author":"L Jennings","year":"2020","unstructured":"Jennings L, Hambly R, Hughes R, Moriarty B, Kirby B. Metformin use in hidradenitis suppurativa. J Dermatolog Treat. 2020;31:261\u20133. https:\/\/doi.org\/10.1080\/09546634.2019.1592100.","journal-title":"J Dermatolog Treat"},{"key":"1680_CR59","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.36849\/JDD.2020.5447","volume":"19","author":"C Moussa","year":"2020","unstructured":"Moussa C, Wadowski L, Price H, Mirea L, O\u2019Haver J. Metformin as adjunctive therapy for pediatric patients with hidradenitis suppurativa. J Drugs Dermatol. 2020;19:1231\u20134. https:\/\/doi.org\/10.36849\/JDD.2020.5447.","journal-title":"J Drugs Dermatol"},{"key":"1680_CR60","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/j.1468-3083.2012.04668.x","volume":"27","author":"R Verdolini","year":"2013","unstructured":"Verdolini R, Clayton N, Smith A, Alwash N, Mannello B. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol. 2013;27:1101\u20138. https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04668.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1680_CR61","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1016\/j.jaad.2012.06.011","volume":"67","author":"L Bianchi","year":"2012","unstructured":"Bianchi L, Hansel K, Stingeni L. Recalcitrant severe hidradenitis suppurativa successfully treated with cyclosporine A. J Am Acad Dermatol. 2012;67:e278\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2012.06.011.","journal-title":"J Am Acad Dermatol"},{"key":"1680_CR62","first-page":"289P","volume":"88","author":"DA Buckley","year":"1995","unstructured":"Buckley DA, Rogers S. Cyclosporin-responsive hidradenitis suppurativa. J R Soc Med. 1995;88:289P-290P.","journal-title":"J R Soc Med"},{"key":"1680_CR63","doi-asserted-by":"crossref","unstructured":"Gupta AK, Ellis CN, Nickoloff BJ, Goldfarb MT, Ho VC, Rocher LL, et\u00a0al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol. 1990;126:339\u201350.","DOI":"10.1001\/archderm.1990.01670270071012"},{"key":"1680_CR64","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/09546634.2015.1088128","volume":"27","author":"MD Anderson","year":"2016","unstructured":"Anderson MD, Zauli S, Bettoli V, Boer J, Jemec GBE. Cyclosporine treatment of severe hidradenitis suppurativa \u2013 A case series. J Dermatolog Treat. 2016;27:247\u201350. https:\/\/doi.org\/10.3109\/09546634.2015.1088128.","journal-title":"J Dermatolog Treat"},{"key":"1680_CR65","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jaad.2016.06.001","volume":"75","author":"D Wong","year":"2016","unstructured":"Wong D, Walsh S, Alhusayen R. Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa. J Am Acad Dermatol. 2016;75:1059\u201362. https:\/\/doi.org\/10.1016\/j.jaad.2016.06.001.","journal-title":"J Am Acad Dermatol"},{"key":"1680_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020294","volume":"14","author":"S Dastoli","year":"2022","unstructured":"Dastoli S, Nistic\u00f2 SP, Morrone P, Patruno C, Leo A, Citraro R, et\u00a0al. Colchicine in managing skin conditions: a systematic review. Pharmaceutics. 2022;14:294. https:\/\/doi.org\/10.3390\/pharmaceutics14020294.","journal-title":"Pharmaceutics"},{"key":"1680_CR67","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bjd.19136","volume":"183","author":"G Murray","year":"2020","unstructured":"Murray G, Hollywood A, Kirby B, Hughes R. Dapsone therapy for hidradenitis suppurativa. Br J Dermatol. 2020;183:767\u20138. https:\/\/doi.org\/10.1111\/bjd.19136.","journal-title":"Br J Dermatol"},{"key":"1680_CR68","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et\u00a0al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375:422\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504370.","journal-title":"N Engl J Med"},{"key":"1680_CR69","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14643","author":"V Muralidharan","year":"2021","unstructured":"Muralidharan V, Pathmarajah P, Peterknecht E, Qazi E, Barlow R, Muralidharan V, et\u00a0al. Real life data on the biopsychosocial effects of adalimumab in the management of hidradenitis suppurativa: a multicenter cross sectional analysis and consideration of a multisystem monitoring approach to follow up. Dermatol Ther. 2021. https:\/\/doi.org\/10.1111\/dth.14643.","journal-title":"Dermatol Ther"},{"key":"1680_CR70","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.ad.2023.05.015","volume":"114","author":"M Mansilla-Polo","year":"2023","unstructured":"Mansilla-Polo M, Escutia-Mu\u00f1oz B, Botella-Estrada R. Narrative review and update on biologic and small molecule drugs for hidradenitis suppurativa: an entity with a promising future. Actas Dermosifiliogr. 2023;114:772\u201383. https:\/\/doi.org\/10.1016\/j.ad.2023.05.015.","journal-title":"Actas Dermosifiliogr"},{"key":"1680_CR71","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2905","volume":"157","author":"S Glatt","year":"2021","unstructured":"Glatt S, Jemec GBE, Forman S, Sayed C, Schmieder G, Weisman J, et\u00a0al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa. JAMA Dermatol. 2021;157:1279. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2905.","journal-title":"JAMA Dermatol"},{"key":"1680_CR72","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.3655","volume":"156","author":"FG Bechara","year":"2021","unstructured":"Bechara FG, Podda M, Prens EP, Horv\u00e1th B, Giamarellos-Bourboulis EJ, Alavi A, et\u00a0al. Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa. JAMA Surg. 2021;156:1001. https:\/\/doi.org\/10.1001\/jamasurg.2021.3655.","journal-title":"JAMA Surg"},{"key":"1680_CR73","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/1744666X.2016.1221762","volume":"12","author":"CC Zouboulis","year":"2016","unstructured":"Zouboulis CC. Adalimumab for the treatment of hidradenitis suppurativa\/acne inversa. Expert Rev Clin Immunol. 2016;12:1015\u201326. https:\/\/doi.org\/10.1080\/1744666X.2016.1221762.","journal-title":"Expert Rev Clin Immunol"},{"key":"1680_CR74","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/bjd.20525","volume":"185","author":"EM S\u00e1nchez Mart\u00ednez","year":"2021","unstructured":"S\u00e1nchez Mart\u00ednez EM, Murray G, Alfageme Rold\u00e1n F, Garc\u00eda Ruiz R, Tobin AM, Zouboulis CC. Adalimumab dose intensification in hidradenitis suppurativa: effectiveness and safety results of a multicentre study. Br J Dermatol. 2021;185:863\u20135. https:\/\/doi.org\/10.1111\/bjd.20525.","journal-title":"Br J Dermatol"},{"key":"1680_CR75","doi-asserted-by":"publisher","unstructured":"Zouboulis CC, Hansen H, Caposiena Caro RD, Damiani G, Delorme I, Pascual JC, et\u00a0al. Adalimumab dose intensification in recalcitrant hidradenitis suppurativa\/Acne inversa. Dermatology [Internet]. S. Karger AG; 2020 [cited 2025 Jun 3];236:25\u201330. https:\/\/doi.org\/10.1159\/000503606,","DOI":"10.1159\/000503606"},{"key":"1680_CR76","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","volume":"81","author":"A Alikhan","year":"2019","unstructured":"Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, et\u00a0al. North American clinical management guidelines for hidradenitis suppurativa: a\u00a0publication from the United States and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2019;81:91\u2013101. https:\/\/doi.org\/10.1016\/j.jaad.2019.02.068.","journal-title":"J Am Acad Dermatol"},{"key":"1680_CR77","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/j.jaad.2015.07.044","volume":"73","author":"A Mehdizadeh","year":"2015","unstructured":"Mehdizadeh A, Hazen PG, Bechara FG, Zwingerman N, Moazenzadeh M, Bashash M, et\u00a0al. Recurrence of hidradenitis suppurativa after surgical management: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;73:S70\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2015.07.044.","journal-title":"J Am Acad Dermatol"},{"key":"1680_CR78","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jaad.2009.12.018","volume":"63","author":"HH van der Zee","year":"2010","unstructured":"van der Zee HH, Prens EP, Boer J. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol. 2010;63:475\u201380. https:\/\/doi.org\/10.1016\/j.jaad.2009.12.018.","journal-title":"J Am Acad Dermatol"},{"key":"1680_CR79","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/ijd.13798","volume":"57","author":"VK Shanmugam","year":"2018","unstructured":"Shanmugam VK, Mulani S, McNish S, Harris S, Buescher T, Amdur R. Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy. Int J Dermatol. 2018;57:62\u20139. https:\/\/doi.org\/10.1111\/ijd.13798.","journal-title":"Int J Dermatol"},{"key":"1680_CR80","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ad.2019.04.008","volume":"111","author":"T Gracia Caza\u00f1a","year":"2020","unstructured":"Gracia Caza\u00f1a T, Berdel D\u00edaz LV, Mart\u00edn S\u00e1nchez JI, Querol Nasarre I, Gilaberte Y. Revisi\u00f3n sistem\u00e1tica de las terapias con luz en el tratamiento de la hidradenitis supurativa. Actas Dermosifiliogr. 2020;111:89\u2013106. https:\/\/doi.org\/10.1016\/j.ad.2019.04.008.","journal-title":"Actas Dermosifiliogr"},{"key":"1680_CR81","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1111\/jdv.15519","volume":"33","author":"PV Chernyshov","year":"2019","unstructured":"Chernyshov PV, Zouboulis CC, Tomas\u2010Aragones L, Jemec GB, Svensson A, Manolache L, et\u00a0al. Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient\u2010Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol. 2019;33:1633\u201343. https:\/\/doi.org\/10.1111\/jdv.15519.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1680_CR82","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/bjd.19337","volume":"183","author":"E Molinelli","year":"2020","unstructured":"Molinelli E, Brisigotti V, Simonetti O, Campanati A, Sapigni C, D\u2019Agostino GM, et\u00a0al. Efficacy and safety of topical resorcinol 15% as long\u2010term treatment of mild\u2010to\u2010moderate hidradenitis suppurativa: a valid alternative to clindamycin in the panorama of antibiotic resistance. Br J Dermatol. 2020;183:1117\u20139. https:\/\/doi.org\/10.1111\/bjd.19337.","journal-title":"Br J Dermatol"},{"key":"1680_CR83","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.jaad.2017.07.008","volume":"77","author":"JC Pascual","year":"2017","unstructured":"Pascual JC, Encabo B, de Ruiz Apodaca RF, Romero D, Selva J, Jemec GB. Topical 15% resorcinol for hidradenitis suppurativa: an uncontrolled prospective trial with clinical and ultrasonographic follow-up. J Am Acad Dermatol. 2017;77:1175\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2017.07.008.","journal-title":"J Am Acad Dermatol"},{"key":"1680_CR84","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2230.2009.03377.x","volume":"35","author":"J Boer","year":"2010","unstructured":"Boer J, Jemec GBE. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol. 2010;35:36\u201340. https:\/\/doi.org\/10.1111\/j.1365-2230.2009.03377.x.","journal-title":"Clin Exp Dermatol"},{"key":"1680_CR85","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12841","author":"A Campanati","year":"2019","unstructured":"Campanati A, Martina E, Giuliodori K, Bobyr I, Consales V, Offidani A. Two cases of hidradenitis suppurativa and botulinum toxin type a therapy: a novel approach for a pathology that is still difficult to manage. Dermatol Ther. 2019. https:\/\/doi.org\/10.1111\/dth.12841.","journal-title":"Dermatol Ther"},{"key":"1680_CR86","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40257-020-00537-9","volume":"21","author":"\u00d8 Grimstad","year":"2020","unstructured":"Grimstad \u00d8, Kvammen B\u00d8, Swartling C. Botulinum toxin type B for hidradenitis suppurativa: a randomised, double-blind, placebo-controlled pilot study. Am J Clin Dermatol. 2020;21:741\u20138. https:\/\/doi.org\/10.1007\/s40257-020-00537-9.","journal-title":"Am J Clin Dermatol"},{"key":"1680_CR87","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jaad.2020.08.113","volume":"85","author":"P Aarts","year":"2021","unstructured":"Aarts P, Vossen ARJV, van der Zee HH, Prens EP, van Straalen KR. Long-term treatment with apremilast in hidradenitis suppurativa: a 2-year follow-up of initial responders. J Am Acad Dermatol. 2021;85:258\u201360. https:\/\/doi.org\/10.1016\/j.jaad.2020.08.113.","journal-title":"J Am Acad Dermatol"},{"key":"1680_CR88","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.ad.2020.06.006","volume":"112","author":"P Garbayo-Salmons","year":"2021","unstructured":"Garbayo-Salmons P, Exp\u00f3sito-Serrano V, Ribera Pibernat M, Roman\u00ed J. Hidradenitis supurativa tratada con apremilast: serie de casos. Actas Dermosifiliogr. 2021;112:936\u20139. https:\/\/doi.org\/10.1016\/j.ad.2020.06.006.","journal-title":"Actas Dermosifiliogr"},{"key":"1680_CR89","first-page":"170","volume":"18","author":"FR Kerdel","year":"2019","unstructured":"Kerdel FR, Azevedo FA, Kerdel Don C, Don FA, Fabbrocini G, Kerdel FA. Apremilast for the treatment of mild-to-moderate hidradenitis suppurativa in a prospective, open-label, phase 2 study. J Drugs Dermatol. 2019;18:170\u20136.","journal-title":"J Drugs Dermatol"},{"key":"1680_CR90","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","volume":"80","author":"ARJV Vossen","year":"2019","unstructured":"Vossen ARJV, van Doorn MBA, van der Zee HH, Prens EP. Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial. J Am Acad Dermatol. 2019;80:80\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.046.","journal-title":"J Am Acad Dermatol"},{"key":"1680_CR91","doi-asserted-by":"publisher","DOI":"10.1007\/s10103-024-04077-0","volume":"39","author":"MA Nilforoushzadeh","year":"2024","unstructured":"Nilforoushzadeh MA, Heidari N, Heidari A, Ghane Y, Hosseini S, Lotfi Z, et\u00a0al. Efficacy and safety of radiofrequency in the treatment of hidradenitis suppurativa; a systematic review. Lasers Med Sci. 2024;39:139. https:\/\/doi.org\/10.1007\/s10103-024-04077-0.","journal-title":"Lasers Med Sci"},{"key":"1680_CR92","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1080\/09546634.2019.1677842","volume":"32","author":"S Wilden","year":"2021","unstructured":"Wilden S, Friis M, Tuettenberg A, Staubach-Renz P, Wegner J, Grabbe S, et\u00a0al. Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF). J Dermatol Treat. 2021;32:530\u20137. https:\/\/doi.org\/10.1080\/09546634.2019.1677842.","journal-title":"J Dermatol Treat"},{"key":"1680_CR93","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jdermsci.2016.08.010","volume":"84","author":"S Hessam","year":"2016","unstructured":"Hessam S, Sand M, Meier NM, Gambichler T, Scholl L, Bechara FG. Combination of oral zinc gluconate and topical triclosan: an anti-inflammatory treatment modality for initial hidradenitis suppurativa. J Dermatol Sci. 2016;84:197\u2013202. https:\/\/doi.org\/10.1016\/j.jdermsci.2016.08.010.","journal-title":"J Dermatol Sci"},{"key":"1680_CR94","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000100883","volume":"214","author":"A Brocard","year":"2007","unstructured":"Brocard A, Knol A-C, Khammari A, Dr\u00e9no B. Hidradenitis suppurativa and zinc: a new therapeutic approach. Dermatology. 2007;214:325\u20137. https:\/\/doi.org\/10.1159\/000100883.","journal-title":"Dermatology"},{"key":"1680_CR95","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/jdv.20472","volume":"39","author":"CC Zouboulis","year":"2025","unstructured":"Zouboulis CC, Bechara FG, Benhadou F, Bettoli V, Bukvi\u0107 Mokos Z, Del Marmol V, et al. European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: Treatment. J Eur Acad Dermatol Venereol. 2025;39:899\u2013941. https:\/\/doi.org\/10.1111\/jdv.20472.","journal-title":"J Eur Acad Dermatol Venereol."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01680-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01680-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01680-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:06:25Z","timestamp":1774371985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01680-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1680"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01680-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ahmed Ameen, Fatima Albreiki, Ayman Alnaeem, Muna Al Murrawi, Huda R. Ali, Raghda Almaashari, Fatima Al-Marzooqi, Jawaher Alnaqbi, Hussein A. Dayem, Mohammed Ahmed, Waqas Saad, Srikumar Goturu, Samir Hantirah, Ashraf Reda and Christos C. Zouboulis declare that they have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}